Shanghai Cell Therapy Group Co., Ltd.

Plus, news about IPOs in Hong Kong, InventisBio and Alligator Bioscience: Bristol Myers Squibb partners with AI Proteins: The deal will focus on designing what the companies describe as “miniproteins” and developing them against targets selected by BMS. AI Proteins will get an undisclosed upfront payment and up to $400 million in milestones. — Max Gelman Terns Pharmaceuticals’ stock rallies on early-stage data for leukemia drug: The company shared early data from a Phase 1 trial assessing TERN-701 in patients with relapsed/refractory chronic myeloid leukemia. Terns CMO Emil Kuriakose said in a news release that there is a “highly encouraging” cumulative major molecular response rate of 50% at three months of treatment, adding that patients on the two lowest doses of the allosteric inhibitor saw “clinically meaningful molecular and hematologic responses.” The company now plans to start dose expansion cohorts in the first half of next year, with more data coming late in 2025. Its stock $TERN was up about 5% on Tuesday morning. — Katherine Lewin Six biotechs apply for Hong Kong listing: Since Nov. 24, at least half a dozen biotech companies have applied for listing on the Hong Kong Stock Exchange. That includes Leads Biolabs , which is partnered with Aditum Bio ; Cloudbreak Pharma , a Santen -allied ophthalmology biotech; CF PharmTech , which is developing an inhaled respiratory drug ; cell banking and cell therapy company Shanghai Cell Therapy Group ; Xuanzhu Biopharmaceutical , which is focused on cancer, digestive diseases and NASH; and immunotherapeutics maker Hanx Biopharmaceuticals . — Kyle LaHucik InventisBio touts Phase 2 data for TYK2 inhibitor in plaque psoriasis: The trial hit the primary endpoint with a “significantly greater proportion” of patients on the drug seeing a 75% or greater improvement in the Psoriasis Area and Severity Index compared to those on placebo. InventisBio also noted that 50% of patients receiving the highest dose of the drug saw a complete clearance of the skin by week 12. The complete data are set to be presented at an upcoming conference. — Katherine Lewin Alligator Bioscience announces possible layoffs, focus on pancreatic cancer drug: The Swedish company announced Monday that it may lay off about 70% of its workforce depending on negotiations with trade unions. The layoffs would impact mostly discovery and non-clinical operations. It plans to operate with 15 full-time employees going forward. While the company’s other assets are under a “strategic review,” Alligator plans to move mitazalimab into Phase 3 development for metastatic pancreatic cancer. — Katherine Lewin

Dublin, May 11, 2023 /PRNewswire/ -- The "Global Stem Cell Partnering Terms and Agreements 2010-2023" report has been added to ResearchAndMarkets.com's offering. The Global Stem Cell Partnering Terms and Agreements 2010-2023 report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in stem cell partnering Partnering agreement structure Partnering contract documents Top deals by value Most active dealmakers Average deal terms for stem cells The report provides a detailed understanding and analysis of how and why companies enter stem cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes. This report provides details of the latest stem cell agreements announced in the life sciences since 2010. The report takes the reader through a comprehensive review stem cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering stem cell partnering deals. The report presents financial deal term values for stem cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals. The middle section of the report explores the leading dealmakers in the stem cell partnering field; both the leading deal values and most active stem cell dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market. One of the key highlights of the report is that over 700 online deal records of actual stem cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. The initial chapters of this report provide an orientation of stem cell dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in stem cell dealmaking since 2010, including details of headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading stem cell deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 25 most active companies in stem cell dealmaking with a brief summary followed by a comprehensive listing of stem cell deals announced by that company, as well as contract documents, where available. Chapter 5 provides a comprehensive and detailed review of stem cell partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of stem cell partnering deals signed and announced since Jan 2010. The chapter is organized by specific stem cell technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand. A comprehensive series of appendices is provided organized by stem cell partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand. The report also includes numerous tables and figures that illustrate the trends and activities in stem cell partnering and dealmaking since 2010. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of stem cell technologies and products. Key benefits Global Stem Cell Partnering Terms and Agreements 2010-2023 provides the reader with the following key benefits: In-depth understanding of stem cell deal trends since 2010 Access to headline, upfront, milestone and royalty data Detailed access to actual stem cell contracts entered into by leading biopharma companies Identify most active stem cell dealmakers since 2010 Insight into terms included in a stem cell partnering agreement, with real world examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies Report scope Global Stem Cell Partnering Terms and Agreements 2010-2023 is intended to provide the reader with an in-depth understanding and access to stem cell trends and structure of deals entered into by leading companies worldwide. Stem Cell Partnering Terms and Agreements includes: Trends in stem cell dealmaking in the biopharma industry since 2010 Access to headline, upfront, milestone and royalty data Access to stem cell contract documents Leading stem cell deals by value since 2010 Most active stem cell dealmakers since 2010 In Global Stem Cell Partnering Terms and Agreements 2010-2023, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target Technology type Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The Global Stem Cell PartneringTerms and Agreements 2010-2023 report provides comprehensive access to available deals and contract documents for over 700 stem cell deals. Analyzing actual contract agreements allows assessment of the following: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Companies Mentioned Regenetech Regeneus Stempeutics Bakulev Center of Cardiovascular Surgery of Russian Academy of Sciences CNA Development The New York Stem Cell Foundation Arthrex Generex Biotechnology Celltex Therapeutics Viscofan BioEngineering Dana-Farber Cancer Institute Biosafe BioLife Solutions Rockefeller University Montefiore Medical Center Wake Forest University Fast Forward Jain Foundation Promega Lineage Cell Therapeutics Hepregen Histogen Lentigen Philogen Vascugen Shenogen Pharma VistaGen Therapeutics Centogene Spinogenix Transgenomic Biological Industries Procognia Apceth Munich Technical University Lehigh University Monash University Abu Dhabi Stem Cells Center Shanghai Cell Therapy Group Shanghai Jia Fu Medical Apparatus Sinopharm AXM Pharma For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets